Guardant Health expects full year 2024 revenue excluding screening to be in the range of $655 to $670 million, representing growth of 16% to 19% compared to full year 2023, and full year 2024 non-GAAP gross margin excluding screening to be in the range of 60% to 62%. Guardant Health expects total non-GAAP operating expenses to be in the range of $740 to $750 million, representing a 1% to 3% increase compared to full year 2023, and free cash flow to be in the range of negative $320 to $330 million in 2024, an improvement compared to the full year 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GH:
- Guardant Health Announces Board Member Samir Kaul’s Resignation
- Guardant Health price target lowered to $54 from $64 at Craig-Hallum
- Guardant Health’s preliminary Q4 results well ahead of consensus, says Canaccord
- Guardant Health sees FY23 revenue $562M-$563M, consensus $555.18M
- Guardant Health reports preliminary Q4 revenue $153M-$154M, consensus $146.34M
Questions or Comments about the article? Write to editor@tipranks.com